Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Urology Reports
Erschienen in: Current Urology Reports 6/2011

01.12.2011 | Overactive Bladder (Gopal Badlani, Section Editor)

Bladder Dysfunction and Parkinsonism: Current Pathophysiological Understanding and Management Strategies

verfasst von: Lysanne Campeau, Roberto Soler, Karl-Erik Andersson

Erschienen in: Current Urology Reports | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Patients with Parkinson’s disease (PD) commonly develop lower urinary tract symptoms (LUTS) as their disease severity progresses. It is a well-established fact that neurodegeneration of the nigrostriatal dopaminergic pathway occurs in PD. This neurochemical deficiency explains many of the motor disturbances encountered in patients with PD. However, the underlying cause of urinary dysfunction present in over half of patients with PD is poorly understood. Without clearly understanding the underlying pathophysiological and neurochemical mechanisms of LUTS associated with PD, treatment strategies are mainly empirical in nature. This review presents the most recent studies and evidence on the pathophysiological mechanisms of PD-related voiding dysfunction and its available therapies.
Literatur
1.
Md R, Breteler M, Graveland G, et al. Prevalence of Parkinson’s disease in the elderly: the Rotterdam Study. Neurology. 1995;45:2143–6.
2.
Winge K, Skau A-M, Stimpel H, Nielsen KK, Werdelin L. Prevalence of bladder dysfunction in Parkinsons disease. Neurourol Urodyn. 2006;25:116–22.PubMedCrossRef
3.
Ransmayr GN, Holliger S, Schletterer K, et al. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology. 2008;70:299–303.PubMedCrossRef
4.
Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24:1641–9.PubMedCrossRef
5.
Sammour ZM, Gomes CM, Barbosa ER, et al. Voiding dysfunction in patients with Parkinson’s disease: impact of neurological impairment and clinical parameters. Neurourol Urodyn. 2009;28:510–5.PubMedCrossRef
6.
Roth B, Studer UE, Fowler CJ, Kessler TM. Benign prostatic obstruction and Parkinson’s disease-should transurethral resection of the prostate be avoided? J Urol. 2009;181:2209–13.PubMedCrossRef
7.
Yoshimura N, Sasa M, Yoshida O, Takaori S. Dopamine D1 receptor mediated inhibition of micturition reflex by central dopamine from the substantia Nigra. Neurourol Urodyn. 1992;11:535–45.CrossRef
8.
Sakakibara R, Nakazawa K, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T. Micturition-related electrophysiological properties in the substantia nigra pars compacta and the ventral tegmental area in cats. Auton Neurosci. 2002;101:30–8.CrossRef
9.
•• Kitta T, Matsumoto M, Tanaka H, Mitsui T, Yoshioka M, Nonomura K. GABAergic mechanism mediated via D1 receptors in the rat periaqueductal gray participates in the micturition reflex: an in vivo microdialysis study. Eur J Neurosci. 2008;27:3216–25. This manuscript elegantly describes the role of the dopaminergic system in the micturition reflex of an animal model of PD. They demonstrated that extracellular GABA in the periaqueductal gray region is increased by both dopamine-1 receptor blockade in normal animals, and by dopamine depletion in the animal model.PubMedCrossRef
10.
Kitta T, Kakizaki H, Furuno T, et al. Brain activation during detrusor overactivity in patients with Parkinson’s disease: a positron emission tomography study. J Urol. 2006;175:994–8.PubMedCrossRef
11.
Matsuura S, Kakizaki H, Mitsui T, Shiga T, Tamaki N, Koyanagi T. Human brain region response to distention or cold stimulation of the bladder: a positron emission tomography study. J Urol. 2002;168(5):2035–9.CrossRef
12.
Winge K, Friberg L, Werdelin L, Nielsen KK, Stimpel H. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson’s disease. Eur J Neurol. 2005;12:842–50.PubMedCrossRef
13.
Seki S, Igawa Y, Kaidoh K, Ishizuka O, Nishizawa O, Andersson K. Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats. Neurourol Urodyn. 2001;20.
14.
Uchiyama T, Sakakibara R, Yoshiyama M, et al. Biphasic effect of apomorphine, an anti-Parkinsonian drug, on bladder function in rats. Neuroscience. 2009;162:1333–8.PubMedCrossRef
15.
Brusa L, Petta F, Pisani A, et al. Central acute D2 stimulation worsens bladder function in patients with mild Parkinson’s disease. J Urol. 2006;175:202–6.PubMedCrossRef
16.
Brusa L, Petta F, Pisani A, et al. Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. Neurology. 2007;68:1455–9.PubMedCrossRef
17.
Uchiyama T, Sakakibara R, Yamamoto T, et al. Comparing bromocriptine effects with levodopa effects on bladder function in Parkinson’s disease. Mov Disord. 2009;24:2386–90.PubMed
18.
Palleschi G, Pastore AL, Stocchi F, et al. Correlation between the Overactive Bladder Questionnaire (OAB-q) and urodynamic data of parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment. Clin Neuropharmacol. 2006;29:220–9.PubMedCrossRef
19.
Katayama Y, Kasai M, Oshima H, et al. Subthalamic nucleus stimulation for Parkinson’s disease: benefits observed in levodopa-intolerant patients. J Neurosurg. 2001;95:213–21.PubMedCrossRef
20.
Limousin P, Pollak P, Benazzouz A, et al. Effect on Parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet. 1995;345:91–5.PubMedCrossRef
21.
Sakakibara R, Nakazawa K, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T. Effects of subthalamic nucleus stimulation on the micturation reflex in cats. Neuroscience. 2003;120:871–5.PubMedCrossRef
22.
Winge K, Nielsen KK, Stimpel H, Lokkegaard A, Jensen SR, Werdelin L. Lower urinary tract symptoms and bladder control in advanced Parkinson’s disease: effects of deep brain stimulation in the subthalamic nucleus. Mov Disord. 2007;22:220–5.PubMedCrossRef
23.
Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Videourodynamic and sphincter motor unit potential analyses in Parkinson’s disease and multiple system atrophy. J Neurol Neurosurg Psychiatry. 2001;71:600–6.PubMedCrossRef
24.
•• Herzog J, Weiss PH, Assmus A, et al. Improved sensory gating of urinary bladder afferents in Parkinson’s disease following subthalamic stimulation. Brain. 2008;131:132–45. This clinical study found that the posterior thalamus and the insular cortex interacted more during the “ON” state of the STN-DBS as compared to the “OFF” state in patients with PD while undergoing bladder filling.PubMedCrossRef
25.
Fritsche H-M, Ganzer R, Schlaier J, Wieland WF, Brawanski A, Lange M. Acute urinary retention in two patients after subthalamic nucleus deep brain stimulation (STN-DBS) for the treatment of advanced Parkinson’s disease. Mov Disord. 2009;24:1553–4.PubMedCrossRef
26.
• Brusa L, Agrò EF, Petta F, et al. Effects of inhibitory rTMS on bladder function in Parkinson’s disease patients. Mov Disord. 2009;24:445–7. This article observed improvement in lower urinary tract symptoms in patients with PD following a 2-week course of low-frequency 1-Hz repetitive transcranial magnetic stimulation, a procedure known to inhibit cortical excitability.PubMedCrossRef
27.
Kulaksizoglu H, Parman Y. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons’s disease. Parkinsonism & Related Disorders. 2010;16(8):531–4.
28.
Giannantoni A, Rossi A, Mearini E, Del Zingaro M, Porena M, Berardelli A. Botulinum toxin a for overactive bladder and detrusor muscle overactivity in Patients with Parkinson’s disease and multiple system atrophy. J Urol. 2009;182:1453–7.PubMedCrossRef
29.
Kabay SC, Kabay S, Yucel M, Ozden H. Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson’s disease. Neurourol Urodyn. 2009;28:62–7.PubMedCrossRef
30.
Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol. 2003;54:403–14.PubMedCrossRef
31.
Soler R, Füllhase C, Santos C, Andersson K. Development of bladder dysfunction in a rat model of dopaminergic brain lesion. Neurourol Urodyn. 2011;30:188–93.PubMedCrossRef
32.
Soler R, Fullhase C, Hanson A, Andersson K, Santos C. Effect of amniotic fluid and bone marrow stem cell therapy on bladder dysfunction in a Parkinson’s disease model [abstract]. Int Urogynecol J. 2010;21:S384–5.
Metadaten
Titel
Bladder Dysfunction and Parkinsonism: Current Pathophysiological Understanding and Management Strategies
verfasst von
Lysanne Campeau
Roberto Soler
Karl-Erik Andersson
Publikationsdatum
01.12.2011
Verlag
Current Science Inc.
Erschienen in
Current Urology Reports / Ausgabe 6/2011
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-011-0219-8

Weitere Artikel der Ausgabe 6/2011

Current Urology Reports 6/2011 Zur Ausgabe

ReviewPaper

Penile Fracture and Penile Reconstruction

Erectile Dysfunction (Tom Lue, Section Editor)

Emerging and Novel Therapeutic Approaches in the Treatment of Male Erectile Dysfunction

Clinical Trial Report

The Scientific Rationale for Using Biomaterials in Stress Urinary Incontinence and Pelvic Organ Prolapse

Overactive Bladder (Gopal Badlani, Section Editor)

Bladder Dysfunction in Patients with Diabetes

Erectile Dysfunction (Tom F. Lue, Section Editor)

Combination Surgery for Erectile Dysfunction and Male Incontinence

Erectile Dysfunction (Thomas Lue, Section Editor)

Rise of Herbal and Traditional Medicine in Erectile Dysfunction Management

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise